Significance | Electromagnetic waves are succesfully utilized for the treatment of angiogenic diseases and diagnosis.
studies in cellular and molecular biology suggest identifying new angiogenic biomarkers and their of vascular endothelial growth factor (Duda, et al., 2007) and its receptor tyrosine kinase (Young and Dyson, 1990) , VEGFR-1 (Kwok et al. 2013 ) and VEGFR-2 (Duda, et al., 2007; Fujii et al., 2013; Kadambi et al., 2001; Tsuzuki et al., 2000; Hicklin and Ellis, 2005) on new tumour blood vessels formation.
Binding of VEGF to its receptor induces a signalling cascade that enhances the proliferation, migration and survival of endothelial cells and nally leads to angiogenesis. Primarily, the angiogenic e ects of the VEGF family are mediated by VEGF-A which is the most-characterized signalling pathway in developmental and tumor angiogenesis (Selleck, 2006; Bagri, 2010; Tortora, 2008; Grothey, 2009 ).
e VEGF/VEGFR signalling pathway plays an e ective role in both normal vasculature development and many other disease processes. e VEGF family has seven members. All members have VEGF homology domain: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-F and placenta growth factor (Cai and Chen, 2006; Ferrara, 2004) .
It has been reported that the isoforms have VEGF-A . is homodimeric, disul de-bound glycoprotein has di erent amino-acid residues, such as VEGF121 and VEGF165. Apart from the di erence in molecular weights, these isoforms di er in their biologic properties in terms of their ability to bind to cell surface heparin sulphate proteoglycans (Ferrara, 2004 (Cosgrove , 2014) . RI measurements are related to microvessel density (MVD) in breast, brain and ovarian cancer, but the connection is indirect since the microvessels are signi cantly below the spatial resolution of ultrasound (Turkbey et al., 2009 ).
Contrast-enhanced ultrasound using microbubbles can detect images from smaller vessels and facilitate the assessment of patient response to anti-angiogenesis treatment in some tumour types. However, due to some constraints in spatial resolution, operator dependence, the short time window for imaging, and the limited eld or view (Hata et al., 1998; Yang et al., 2002; Alcazar, 2006) this type of ultrasound has not been extensively used.
Ultrasound Imaging of VEGFRs and Endostatin
Some features (e.g.safety, low cost, ease of use, and wide availability) (Bloch et al., 2004) of ultrasound (ultrasonography) has made it the most commonly used clinical imaging system. e contrast of ultrasound depends on four major parameters, such as sound speed, sound attenuation, imaging algorithm, and backscatter (Wink et al., 2006) . Ultrasound can be used to depict the microcirculation with two methods of Doppler and microbubble methods (Liang and Blomley, 2014 (Drevs et al., 2000; Forsberg et al., 2004; Forsberg et al., 2002; Cheung et al., 20070 . However, the data have not shown non-invasive direct imaging of VEGF/VEGFR expression and only new ultrasound imaging of VEGF/VEGFR expression was not reported (Korpanty et al., 2007) .
Contrast-enhanced ultrasound (Kittel et al., 1976) imaging usually uses microbubbles, that are roughly a micrometer in size.
is means that only the tumour endothelium can be targeted, since these microbubbles are too large to extravasate. In a mouse model of pancreatic cancer, targeted microbubbles were utilized to re ect and calculate the vascular e ects of two anti-tumour therapies on both subcutaneous and orthotopic pancreatic tumours e targeted microbubbles produced a remarkably higher average video signal intensity compared to control microbubbles in both tumour models. Whereas, the video signal intensity was also lower when anti-VEGFR-2 antibodies (blocking antibodies)
were used, to show target speci city. ese reports show that targeted microbubbles can be a unique and attractive tool for the imaging of tumour angiogenesis, like for the in vivo demonstrating of vascular e ects a er therapy. Ultrasound has a high spatial resolution in range of 50-500 μm, however it also has some disadvantages, such as relatively poor tissue penetration (generally a few centimetres, depends on the frequency used) and limited sensitivity (Massoud and Gambhir, 2003) .
In addition, further development of molecular imaging with ultrasound might allow molecular imaging of a greater number of diseases, which will advance in technology for ligand attachment to microbubbles, greater characterization of the acoustic behaviour of targeted contrast agents, and more sensitive methods. Acoustic failure of "payload-bearing" microbubbles has been used to deliver drugs or to adjoin gene transfection (Shohet et al., 2000) . us, angiogenesis-targeted microbubbles may also have future applications in site-speci c cancer therapy (Young and Dyson, 1990) .
Cationic liposomes consist of plasmid DNA attached to the phospholipid shell of gas-lled microbubbles 2-4 µm in diame-
ter. e microbubble-liposome complexes are infused intravenously (i.v.) and destructed within the myocardial microcirculation by low-frequency ultrasound .
e targeted endostatin microbubbles, complexed with focused, directional ultrasound radiation can destroy tumour microvasculature of subcutaneous colon translocation in situ colon cancer, so inhibits the tumour angiogenesis (Kwok et al., 2013) . Ultrasound-targeted microbubble destruction (UTMD) can be utilized to deliver silencing gene therapy to tumours. Researchers hypothesized that UTMD would be e ective in suppressing angiogenesis within tumours, and that the magnitude of target knockdown will be a ected by the modulation of the ultrasound pulsing intervals during UTMD.
UTMD of vascular endothelial growth factor receptor-2 (VEG-FR2) short hairpin (sh)RNA plasmid in an heterotopic mammary adenocarcinoma model in rats was used to evaluate PIs of 2, 5, 10, and 20 seconds. e ndings that UTMD with a PI of 10 seconds led to a more e cient knockdown of VEGFR2 by PCR, immunostaining, western blotting as well as smaller tumor volumes and perfused areas, and lower tumour microvascular blood volume (MBV) and ow by contrast-enhanced ultrasound (Kittel et al., 2010) relative to UTMD-treated tumours at 2, 5, and 20 seconds, control tumours, tumours treated with intravenous shRNA plasmid and scrambled plasmid.
CEU perfusion assessment using a therapeutic probe showed that tumors were fully replenished with microbubbles within 10 seconds, but incompletely replenished at PI-2 and PI-5 seconds.
Finally, for anti-VEGFR2 cancer gene therapy by UTMD, PI of 10 seconds leads to higher target knock down and a more anti-angiogenic e ect. Complete replacing of tumour vasculature with silencing gene-bearing microbubbles in between destructive pulses of UTMD is needed to maximize the e cacy of anti-angiogenic cancer gene therapy (Fujii, H., et al., 2013) .
Contrast-enhanced ultrasound
Contrast-enhanced ultrasound (Kittel et al., 2010) (Dewitte et al., 2011) .
e ability to distinguish the rst molecular changes that happen in angiogenesis, before changes in perfusion or vascular morphology, would allow early monitoring of therapies. In pre-clinical studies, such techniques could also produce data on the physiological responses to angiogenic and cell-based therapies, which clari es future insight into mechanisms related to the pro-angiogenic response.
Conclusion
In conclusion, molecular ultrasound is a hopeful quantitative technology for imaging of multiple angiogenic markers. It prepares a high sensitivity as contrast agents, excellent biocompatibility, and meaningful potential for clinical translation. It is suitable for the identi cation of angiogenic markers as well as the evaluation of anti-angiogenic therapy e ects. us, utilizing molecular ultrasound suggests multiple options to develop biomedical research in the future.
